Broadly neutralizing antibodies to SARS-related viruses can be readily induced in rhesus macaques
暂无分享,去创建一个
Yana Safonova | D. Irvine | D. Burton | I. Wilson | A. Sette | B. Briney | D. Nemazee | A. Ward | Davey M. Smith | S. Crotty | J. Torres | M. Yuan | D. Weiskopf | Stephen A. Rawlings | Xueyong Zhu | J. Dan | Melissa Ferguson | M. Melo | R. Andrabi | T. Rogers | N. Beutler | Murillo Silva | Deli Huang | Bryan S. Briney | William J Rinaldi | Wan-ting He | G. Song | Panpan Zhou | Linghang Peng | Fangzhu Zhao | F. Anzanello | R. Musharrafieh | Sean Callaghan | Peter Yong | M. Parren | Elijah Garcia | Zeli Zhang | James Ricketts | Wen‐Hsin Lee | E. Garcia | Wen‐Hsin Lee | Rami Musharrafieh | William J. Rinaldi
[1] Lisa E. Gralinski,et al. Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses , 2022, Nature Immunology.
[2] D. Burton,et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection , 2022, Science Translational Medicine.
[3] J. Mascola,et al. SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination , 2022, The New England journal of medicine.
[4] D. Burton,et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection , 2022, bioRxiv.
[5] Gregory D. Gromowski,et al. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates , 2021, Science Translational Medicine.
[6] J. Mascola,et al. Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization , 2021, medRxiv.
[7] D. Irvine,et al. A particulate saponin/TLR agonist vaccine adjuvant alters lymph flow and modulates adaptive immunity , 2021, Science Immunology.
[8] Aaron M. Rosenfeld,et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern , 2021, Science.
[9] B. Pulendran,et al. Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines , 2021, Cell.
[10] Rommie E. Amaro,et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma , 2021, Proceedings of the National Academy of Sciences.
[11] B. Haynes,et al. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates , 2021, Science Translational Medicine.
[12] M. Beltramello,et al. Broad sarbecovirus neutralization by a human monoclonal antibody , 2021, Nature.
[13] C. Woods,et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies , 2021, Cell.
[14] C. Rice,et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection , 2021, Nature.
[15] X. Xie,et al. Humoral immune response to circulating SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines , 2021, Cell Research.
[16] D. Burton,et al. Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection , 2021, Nature Communications.
[17] Rachel L. Spreng,et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses , 2021, Nature.
[18] Daniel W. Kulp,et al. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection , 2021, bioRxiv.
[19] J. Mascola,et al. Immune Correlates of Protection by mRNA-1273 Immunization against SARS-CoV-2 Infection in Nonhuman Primates , 2021, bioRxiv.
[20] B. Pulendran,et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity , 2021, Nature.
[21] F. Krammer. Correlates of protection from SARS-CoV-2 infection , 2021, The Lancet.
[22] P. Klenerman,et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) , 2021, The Lancet.
[23] D. Burton,et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection , 2021, bioRxiv.
[24] L. Stamatatos,et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection , 2021, Science.
[25] D. Ho,et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 , 2021, Nature.
[26] B. Haynes,et al. Vaccination with SARS-CoV-2 Spike Protein and AS03 Adjuvant Induces Rapid Anamnestic Antibodies in the Lung and Protects Against Virus Challenge in Nonhuman Primates , 2021, bioRxiv.
[27] John P. Moore,et al. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans , 2021, Science Advances.
[28] D. Irvine,et al. Disassembly of HIV envelope glycoprotein trimer immunogens is driven by antibodies elicited via immunization , 2021, bioRxiv.
[29] Dapeng Zhou,et al. Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19 , 2021, bioRxiv.
[30] D. Burton,et al. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants , 2021, Science.
[31] J. Mascola,et al. SARS-CoV-2 Viral Variants-Tackling a Moving Target. , 2021, JAMA.
[32] M. Nussenzweig,et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, Nature.
[33] B. Murrell,et al. Rhesus and cynomolgus macaque immunoglobulin heavy-chain genotyping yields comprehensive databases of germline VDJ alleles , 2021, Immunity.
[34] M. Nussenzweig,et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants , 2021, bioRxiv.
[35] L. Morris,et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma , 2021, bioRxiv.
[36] N. Patel,et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.
[37] M. Nussenzweig,et al. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice , 2020, Science.
[38] W. Chiu,et al. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice , 2021, ACS central science.
[39] M. Seong,et al. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals , 2021, Science Translational Medicine.
[40] C. Woods,et al. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates , 2021, bioRxiv.
[41] G. B. Karlsson Hedestam,et al. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice , 2020, EBioMedicine.
[42] Rommie E. Amaro,et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma , 2020, bioRxiv.
[43] G. Gao,et al. Viral targets for vaccines against COVID-19 , 2020, Nature reviews. Immunology.
[44] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[45] D. Lauffenburger,et al. Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.
[46] Lisa E. Gralinski,et al. Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 , 2020, Cell.
[47] M. Nussenzweig,et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies , 2020, Nature.
[48] Yong-tang Zheng,et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates , 2020, Nature Communications.
[49] D. Burton,et al. Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection , 2020, bioRxiv.
[50] F. Krammer. SARS-CoV-2 vaccines in development , 2020, Nature.
[51] M. Beltramello,et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology , 2020, Cell.
[52] X. Xie,et al. Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy , 2020, Cell.
[53] W. Chiu,et al. A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice , 2020, bioRxiv.
[54] J. Bloom,et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with high attack rate , 2020, medRxiv.
[55] Rebecca J. Loomis,et al. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates , 2020, The New England journal of medicine.
[56] C. Rice,et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants , 2020, bioRxiv.
[57] Lisa E. Gralinski,et al. Potently neutralizing and protective human antibodies against SARS-CoV-2 , 2020, Nature.
[58] J. Mascola,et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report , 2020, The New England journal of medicine.
[59] D. Burton,et al. Structural basis of a shared antibody response to SARS-CoV-2 , 2020, Science.
[60] M. Nussenzweig,et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies , 2020, Cell.
[61] J. Dye,et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies , 2020, Science.
[62] D. Burton,et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.
[63] R. Welsh,et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail , 2020, Science.
[64] C. Rice,et al. Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals , 2020, Nature.
[65] M. Nussenzweig,et al. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies , 2020, bioRxiv.
[66] Linqi Zhang,et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, Nature.
[67] William J. Liu,et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.
[68] Amalio Telenti,et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody , 2020, Nature.
[69] X. Xie,et al. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients’ B Cells , 2020, Cell.
[70] M. V. van Breemen,et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability , 2020, Science.
[71] F. Gao,et al. A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2 , 2020, Science.
[72] I. Wilson,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[73] F. Krammer,et al. SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.
[74] Linqi Zhang,et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor , 2020, Nature.
[75] Lei Liu,et al. Potent human neutralizing antibodies elicited by SARS-CoV-2 infection , 2020, bioRxiv.
[76] Nicholas C. Wu,et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections , 2020, bioRxiv.
[77] Nicholas C. Wu,et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV , 2020, Science.
[78] K. Eric Wommack,et al. Iroki: automatic customization and visualization of phylogenetic trees , 2020, PeerJ.
[79] M. Letko,et al. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses , 2020, Nature Microbiology.
[80] B. Graham,et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.
[81] Daniel W. Kulp,et al. Engineered immunogen binding to alum adjuvant enhances humoral immunity , 2020, Nature Medicine.
[82] Matthew R. McKay,et al. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies , 2020, bioRxiv.
[83] Gavin J. D. Smith,et al. Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2 , 2020, Emerging microbes & infections.
[84] Daniel W. Kulp,et al. Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance , 2018, Cell.
[85] Chaim A. Schramm,et al. Isolation and Structure of an Antibody that Fully Neutralizes Isolate SIVmac239 Reveals Functional Similarity of SIV and HIV Glycan Shields. , 2019, Immunity.
[86] Dimitri Schritt,et al. Modeling of stimuli-responsive nanoreactors: rational rate control towards the design of colloidal enzymes , 2019, Molecular Systems Design & Engineering.
[87] Daniel W. Kulp,et al. Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance , 2018, Cell.
[88] D. Burton,et al. Commonality despite exceptional diversity in the baseline human antibody repertoire , 2018, Nature.
[89] F. Alt,et al. Glycan Masking Focuses Immune Responses to the HIV‐1 CD4‐Binding Site and Enhances Elicitation of VRC01‐Class Precursor Antibodies , 2018, Immunity.
[90] Yana Safonova,et al. Reconstructing Antibody Repertoires from Error-Prone Immunosequencing Reads , 2017, The Journal of Immunology.
[91] Matthew Angel,et al. Defining B Cell Immunodominance to Viruses , 2017, Nature Immunology.
[92] F. Alt,et al. Human Ig knockin mice to study the development and regulation of HIV‐1 broadly neutralizing antibodies , 2017, Immunological reviews.
[93] Daniel G. Anderson,et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination , 2016, Proceedings of the National Academy of Sciences.
[94] F. Alt,et al. Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires , 2016, Cell.
[95] David Nemazee,et al. Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies , 2016, Cell.
[96] Barney S. Graham,et al. Pre-fusion structure of a human coronavirus spike protein , 2016, Nature.
[97] John P. Moore,et al. Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes , 2015, Cell.
[98] Lisa E. Gralinski,et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.
[99] David Nemazee,et al. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.
[100] John P. Moore,et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.
[101] L. Macdonald,et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice , 2014, Proceedings of the National Academy of Sciences.
[102] Anneliese O. Speak,et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery , 2014, Nature Biotechnology.
[103] Michael J. Osborn,et al. High-Affinity IgG Antibodies Develop Naturally in Ig-Knockout Rats Carrying Germline Human IgH/Igκ/Igλ Loci Bearing the Rat CH Region , 2013, The Journal of Immunology.
[104] Sjors H.W. Scheres,et al. RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.
[105] Martin H. Koldijk,et al. A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses , 2011, Science.
[106] P. Emsley,et al. Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.
[107] Randy J. Read,et al. Acta Crystallographica Section D Biological , 2003 .
[108] Wolfgang Kabsch,et al. Integration, scaling, space-group assignment and post-refinement , 2010, Acta crystallographica. Section D, Biological crystallography.
[109] M Radermacher,et al. DoG Picker and TiltPicker: software tools to facilitate particle selection in single particle electron microscopy. , 2009, Journal of structural biology.
[110] Michel C Nussenzweig,et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.
[111] Rodrigo Lopez,et al. Clustal W and Clustal X version 2.0 , 2007, Bioinform..
[112] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[113] Jaap Goudsmit,et al. Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants , 2006, PLoS medicine.
[114] Anchi Cheng,et al. Automated molecular microscopy: the new Leginon system. , 2005, Journal of structural biology.
[115] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[116] D. Roote,et al. Status Report , 2006, Journal of periodontology.